74 filings
8-K
FSTX
F-star Therapeutics Inc
9 Mar 23
Completion of Acquisition or Disposition of Assets
8:27am
8-K
FSTX
F-star Therapeutics Inc
7 Mar 23
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
9:08am
8-K
FSTX
F-star Therapeutics Inc
6 Mar 23
Entry into a Material Definitive Agreement
9:31am
8-K
FSTX
F-star Therapeutics Inc
23 Feb 23
Entry into a Material Definitive Agreement
8:45am
8-K
FSTX
F-star Therapeutics Inc
9 Feb 23
Entry into a Material Definitive Agreement
9:01am
8-K
v6ji5r5
1 Feb 23
Entry into a Material Definitive Agreement
8:44am
8-K
o56fwzz
30 Dec 22
Entry into a Material Definitive Agreement
8:37am
8-K
7mo4ac
29 Dec 22
Other Events
9:02am
8-K
ol4m1q3imc 706
21 Dec 22
Entry into a Material Definitive Agreement
6:08am
8-K
mvukqpo 8zfoyv4dw
19 Dec 22
Entry into a Material Definitive Agreement
11:57am
8-K
ogg6rtg8
21 Nov 22
Entry into a Material Definitive Agreement
6:36am
8-K
94q5x
1 Nov 22
Other Events
8:58am
8-K
lvm2kfucxvd nll
11 Aug 22
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
9:20am
8-K
u9gz0u9kz0zw
23 Jun 22
Invox Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
9:25am
8-K
uw7dh010w
16 Jun 22
Submission of Matters to a Vote of Security Holders
5:18pm
8-K
j6ohh88
10 May 22
F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:22am
8-K
xbj5c3kq
14 Mar 22
F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update
8:09am
8-K
gdg88cz4iogyrqj nr
6 Jan 22
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
8:16am
8-K
nhl8nh
12 Nov 21
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
8:34am
8-K
e9qwx5 gvth1
10 Nov 21
F-star Therapeutics Reports Third Quarter 2021 Financial Results
8:30am